Douglas Hanniford, Ph.D.
Affiliations: | 2012 | Basic Medical Science | New York University, New York, NY, United States |
Area:
Oncology, Cell Biology, Molecular BiologyGoogle:
"Douglas Hanniford"Parents
Sign in to add mentor| Eva Hernando-Monge | grad student | 2012 | NYU | |
| (Early alterations of microRNA expression predict and functionally impact melanoma metastasis.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Orlow I, Sadeghi KD, Edmiston SN, et al. (2023) InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma. Plos One. 18: e0269324 |
| Hanniford D, Ulloa-Morales A, Karz A, et al. (2020) Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis. Cancer Cell. 37: 55-70.e15 |
| Floristán A, Morales L, Hanniford D, et al. (2019) Functional analysis of RPS27 mutations and expression in melanoma. Pigment Cell & Melanoma Research |
| Koetz-Ploch L, Hanniford D, Dolgalev I, et al. (2017) MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell & Melanoma Research |
| Simpson D, Ferguson R, Martinez CN, et al. (2017) Mutation burden as a potential prognostic marker of melanoma progression and survival. Journal of Clinical Oncology. 35: 9567-9567 |
| Paoluzzi L, Hanniford D, Sokolova E, et al. (2016) BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma. Cancer Medicine |
| Barbáchano A, Fernández-Barral A, Pereira F, et al. (2015) SPROUTY-2 represses the epithelial phenotype of colon carcinoma cells via upregulation of ZEB1 mediated by ETS1 and miR-200/miR-150. Oncogene |
| Weiss SA, Hanniford D, Hernando E, et al. (2015) Revisiting determinants of prognosis in cutaneous melanoma. Cancer |
| Hanniford D, Zhong J, Koetz L, et al. (2015) A miRNA-based signature detected in primary melanoma tissue predicts development of brain metastasis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Paoluzzi L, Hanniford D, Sokolova E, et al. (2015) Abstract 3522: BET and BRAF inhibitors act synergistically against BRAF mutant melanoma Cancer Research. 75: 3522-3522 |